Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 prophylaxis to prevent chronic GVHD after haploidentical transplantation
ChiCTR2000034198Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jun 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in graft-versus-host disease (GVHD), Acute Graft-Versus-Host Disease (aGvHD) and leukemia, sponsored by Peking University People's Hospital. Primary endpoint: Incidence of moderate to severe chronic GVHD at 1 year post-transplantation. Started Jun 2020; status: recruiting.
02
Drugs
aldesleukin
03
Conditions
graft-versus-host disease (GVHD)Acute Graft-Versus-Host Disease (aGvHD)leukemia
Beyond the preview
Go deeper on ChiCTR2000034198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034198.